Back to search

Netherlands· NL-f28de15a3cc4

Oxiore 500 mg/ml drank

A sodium oxybate product containing natriumhydroxybutyraat, registered in Netherlands by Oresund Pharma ApS. The same ATC class is registered in 14 of our 19 countries.

ATC N07XX04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOxiore 500 mg/ml drankATCN07XX04REGISTER NO.NL-f28de15a3cc4PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Sodium oxybate is registered in 14 of 19 countries.

Countries holding a registration under ATC N07XX04 (sodium oxybate), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose

Sodium oxybate · ATC N07XX04

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
NATRIUMHYDROXYBUTYRAAT
Manufacturer
Oresund Pharma ApS
Country
Netherlands (NL)
ATC code
N07XX04
ATC class
Sodium oxybate
Defined daily dose
7.5 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    125219

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

65 interactions on record for sodium oxybate.

Graded by severity as the source publishes them — 54 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Sodium oxybate · interactions on record

65 records

  • 54 severe
  • 11 moderate

Most severe, free to view

  • MetoclopramideA03FA01severe
  • ThiethylperazinA04AB03severe
  • DiphenhydraminA04AB05severe
  • DronabinolA04AD10severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dcbc1a95-e0fd-4e03-b62e-48ef7b6531f7
GET /v1/drugs/dcbc1a95-e0fd-4e03-b62e-48ef7b6531f7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Drank",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h125219_smpc.pdf",
  "strength": null,
  "atc_label": "Sodium oxybate",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg125219",
  "excipients": [
    "APPELZUUR, (DL)(+-)(E 296)",
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "NATRIUMHYDROXYBUTYRAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h125219.pdf",
  "authorised_at": "2020/12/02",
  "procedure_number": "NL/H/4915/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "125219",
  "additional_monitoring": "N"
}

See everything about sodium oxybate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.